Minimally invasive surgery (MIS) is being validated for pancreatic cancer, impacting how surgeons approach patient selection and procedures.

• 22 out of 28 statements on MIS received over 90% expert agreement, enhancing surgical guidance.
• The consensus includes recommendations for left pancreatectomy, pancreatoduodenectomy, and total pancreatectomy tailored for cancer.

Surgeons can adopt these evidence-based practices to improve patient outcomes and program implementation.

• Insights on evaluating patients and integrating innovation in surgical techniques are also provided.

Surgeons can now better assess resectability in pancreatic cancer by focusing on specific vascular targets.

• Introducing a clear definition: “suitable target” vessels determine anatomic resectability, improving clarity in patient selection.
• Emphasizes the importance of 3D CT imaging and intraoperative assessment of vascular isolation for successful reconstruction.

Adopting this approach enhances surgical eligibility evaluations and has the potential to shift treatment paradigms in locally advanced disease.

• Highlights the need for expert centers to implement these methods for optimal patient outcomes.

Splanchnic venous thrombosis is a critical yet often overlooked risk after splenectomy in hematologic patients.

• Incidence is 11.4%, rising to 20.7% with routine imaging and 15.1% in single-center studies.
• Major risk factors include splenic size and weight; age, BMI, and platelet count were not significant.
• Patients with myeloproliferative neoplasms, lymphoma, and thalassemia face the highest disease-specific risk.

Implementing shared guidelines will aid in personalized prevention and management strategies for these high-risk patients.